Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.09
TEVA's Cash to Debt is ranked lower than
57% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. TEVA: 0.09 )
TEVA' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.09

Equity to Asset 0.50
TEVA's Equity to Asset is ranked higher than
58% of the 728 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. TEVA: 0.50 )
TEVA' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.6
Current: 0.5

0.39
0.6
Interest Coverage 5.25
TEVA's Interest Coverage is ranked higher than
51% of the 454 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.71 vs. TEVA: 5.25 )
TEVA' s 10-Year Interest Coverage Range
Min: 3.6   Max: 328.25
Current: 5.25

3.6
328.25
F-Score: 8
Z-Score: 2.25
M-Score: -2.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 8.12
TEVA's Operating margin (%) is ranked higher than
72% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. TEVA: 8.12 )
TEVA' s 10-Year Operating margin (%) Range
Min: 8.12   Max: 26.78
Current: 8.12

8.12
26.78
Net-margin (%) 6.25
TEVA's Net-margin (%) is ranked higher than
71% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. TEVA: 6.25 )
TEVA' s 10-Year Net-margin (%) Range
Min: 5.73   Max: 21.09
Current: 6.25

5.73
21.09
ROE (%) 5.62
TEVA's ROE (%) is ranked higher than
68% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. TEVA: 5.62 )
TEVA' s 10-Year ROE (%) Range
Min: 3.9   Max: 22.43
Current: 5.62

3.9
22.43
ROA (%) 2.67
TEVA's ROA (%) is ranked higher than
68% of the 777 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. TEVA: 2.67 )
TEVA' s 10-Year ROA (%) Range
Min: 1.93   Max: 11.68
Current: 2.67

1.93
11.68
ROC (Joel Greenblatt) (%) 18.01
TEVA's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.60 vs. TEVA: 18.01 )
TEVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 12.03   Max: 47.4
Current: 18.01

12.03
47.4
Revenue Growth (%) 10.90
TEVA's Revenue Growth (%) is ranked higher than
78% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. TEVA: 10.90 )
TEVA' s 10-Year Revenue Growth (%) Range
Min: 7.8   Max: 23.4
Current: 10.9

7.8
23.4
EBITDA Growth (%) -10.40
TEVA's EBITDA Growth (%) is ranked higher than
59% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. TEVA: -10.40 )
TEVA' s 10-Year EBITDA Growth (%) Range
Min: -10.4   Max: 47.2
Current: -10.4

-10.4
47.2
EPS Growth (%) -25.60
TEVA's EPS Growth (%) is ranked higher than
56% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. TEVA: -25.60 )
TEVA' s 10-Year EPS Growth (%) Range
Min: -25.6   Max: 69.8
Current: -25.6

-25.6
69.8
» TEVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

TEVA Guru Trades in Q3 2013

Murray Stahl 9,460 sh (New)
George Soros 3,608,000 sh (New)
Diamond Hill Capital 264,149 sh (+154.81%)
Steven Cohen 15,918 sh (+43.42%)
Vanguard Health Care Fund 13,145,600 sh (+15.71%)
Pioneer Investments 851,378 sh (+11.66%)
David Dreman 164,964 sh (+6.23%)
Richard Snow 1,427,022 sh (+4.51%)
Manning & Napier Advisors, Inc 254,956 sh (+1.37%)
James Barrow 6,759,766 sh (+0.53%)
Ronald Muhlenkamp 169,985 sh (+0.19%)
Tom Gayner 700,000 sh (+0.14%)
Michael Price 350,000 sh (unchged)
Jean-Marie Eveillard 200 sh (unchged)
Bernard Horn 52,800 sh (unchged)
David Abrams Sold Out
Jim Simons Sold Out
Caxton Associates Sold Out
NWQ Managers 6,132,913 sh (-9.52%)
» More
Q4 2013

TEVA Guru Trades in Q4 2013

Alan Fournier 130,000 sh (New)
Stanley Druckenmiller 1,241,000 sh (New)
Caxton Associates 42,900 sh (New)
George Soros 9,316,000 sh (+158.2%)
James Barrow 12,143,563 sh (+79.64%)
Murray Stahl 13,902 sh (+46.96%)
Richard Snow 1,976,831 sh (+38.53%)
Diamond Hill Capital 348,631 sh (+31.98%)
Michael Price 400,000 sh (+14.29%)
Ronald Muhlenkamp 176,340 sh (+3.74%)
Jean-Marie Eveillard 200 sh (unchged)
George Soros 1,425,000 sh (unchged)
Vanguard Health Care Fund 13,145,600 sh (unchged)
Bernard Horn 52,800 sh (unchged)
Tom Gayner 699,900 sh (-0.01%)
NWQ Managers 5,992,360 sh (-2.29%)
Manning & Napier Advisors, Inc 231,489 sh (-9.2%)
David Dreman 147,328 sh (-10.69%)
Steven Cohen 12,509 sh (-21.42%)
Pioneer Investments 78,418 sh (-90.79%)
» More
Q1 2014

TEVA Guru Trades in Q1 2014

Jeremy Grantham 13,400 sh (New)
Ken Heebner 95,000 sh (New)
Paul Tudor Jones 300,000 sh (New)
John Keeley 47,435 sh (New)
Steven Cohen 2,111,200 sh (+16777.4%)
David Dreman 183,323 sh (+24.43%)
Bernard Horn 65,600 sh (+24.24%)
Murray Stahl 16,553 sh (+19.07%)
George Soros 10,310,041 sh (+10.67%)
James Barrow 13,335,767 sh (+9.82%)
NWQ Managers 6,294,655 sh (+5.04%)
Jean-Marie Eveillard 200 sh (unchged)
Stanley Druckenmiller 1,241,000 sh (unchged)
Manning & Napier Advisors, Inc 231,252 sh (-0.1%)
Ronald Muhlenkamp 175,440 sh (-0.51%)
Tom Gayner 694,000 sh (-0.84%)
Michael Price 388,400 sh (-2.9%)
Vanguard Health Care Fund 12,350,900 sh (-6.05%)
Richard Snow 1,708,890 sh (-13.55%)
Diamond Hill Capital 250,886 sh (-28.04%)
Alan Fournier 50,000 sh (-61.54%)
Pioneer Investments 17,818 sh (-77.28%)
Caxton Associates 5,900 sh (-86.25%)
» More
Q2 2014

TEVA Guru Trades in Q2 2014

Jim Simons 504,663 sh (New)
Pioneer Investments 227,765 sh (+1178.29%)
Michael Price 500,000 sh (+28.73%)
Caxton Associates 7,200 sh (+22.03%)
Manning & Napier Advisors, Inc 264,965 sh (+14.58%)
Richard Snow 1,826,799 sh (+6.9%)
Ronald Muhlenkamp 176,855 sh (+0.81%)
Stanley Druckenmiller 1,241,000 sh (unchged)
John Keeley 47,435 sh (unchged)
Tom Gayner 694,000 sh (unchged)
Jean-Marie Eveillard 200 sh (unchged)
Steven Cohen 1,020,700 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Ken Heebner Sold Out
Alan Fournier Sold Out
Paul Tudor Jones Sold Out
Murray Stahl 15,782 sh (-4.66%)
Diamond Hill Capital 231,779 sh (-7.62%)
David Dreman 159,090 sh (-13.22%)
Jeremy Grantham 11,400 sh (-14.93%)
James Barrow 10,868,770 sh (-18.5%)
NWQ Managers 5,085,717 sh (-19.21%)
George Soros 7,273,240 sh (-29.45%)
Vanguard Health Care Fund 7,344,400 sh (-40.54%)
» More
» Details

Insider Trades

Latest Guru Trades with TEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Reduce -29.45%1.59%$48.69 - $54.06 $ 52.523%7273240
Vanguard Health Care Fund 2014-06-30 Reduce -40.54%0.73%$48.69 - $54.06 $ 52.523%7344400
Michael Price 2014-06-30 Add 28.73%0.71%$48.69 - $54.06 $ 52.523%500000
James Barrow 2014-06-30 Reduce -18.5%0.19%$48.69 - $54.06 $ 52.523%10868770
George Soros 2014-03-31 Add 10.67%0.52%$39.88 - $50.22 $ 52.5214%10310041
David Dreman 2014-03-31 Add 24.43%0.15%$39.88 - $50.22 $ 52.5214%183323
John Keeley 2014-03-31 New Buy0.04%$39.88 - $50.22 $ 52.5214%47435
George Soros 2013-12-31 Add 158.2%1.96%$36.59 - $41.7 $ 52.5233%9316000
James Barrow 2013-12-31 Add 79.64%0.31%$36.59 - $41.7 $ 52.5233%12143563
Michael Price 2013-12-31 Add 14.29%0.26%$36.59 - $41.7 $ 52.5233%400000
David Abrams 2013-09-30 Sold Out 5.8%$37.43 - $41.27 $ 52.5235%0
George Soros 2013-09-30 New Buy1.5%$37.43 - $41.27 $ 52.5235%3608000
Vanguard Health Care Fund 2013-09-30 Add 15.71%0.23%$37.43 - $41.27 $ 52.5235%13145600
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Teva Pharmaceutical Industries Ltd

Diamond Hill Capital Comments on Teva Pharmaceutical Industries Ltd - Jun 26, 2014

Generic drug manufacturer Teva Pharmaceutical Industries Ltd. (TEVA) benefitted from the addition of a well-respected CEO and the continued successful transition of patients to a new, patent-protected version of the company’s multiple sclerosis drug.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

Diamond Hill Capital Comments on Teva Pharmaceutical Industries Ltd
Generic drug manufacturer Teva Pharmaceutical Industries Ltd. (TEVA) benefitted from the addition of a well-respected CEO and the continued successful transition of patients to a new, patent-protected version of the company’s multiple sclerosis drug. Read more...
Diamond Hill Select Fund Commentary – First Quarter 2014
The Fund increased 3.08% (Class I) during the quarter, compared to a 1.97% increase in the Russell 3000 Index. Read more...
Top Guru Held Asian Companies of the First Quarter
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Asian countries were held by the highest number of gurus. The following five companies come from a variety of industries, are Asian-based and are held by the largest number of gurus. Read more...
George Soros Reports Top Five Stocks
George Soros (Trades, Portfolio) and his fund Soros Fund Management recently announced their first quarter portfolio holdings which highlighted 151 new buys. The fund now holds on to 305 stocks valued at over $10.1 billion. The following five stocks are his five largest holdings as of the close of the first quarter. Read more...
Richard Snow's Top Five Highlight Finance and Healthcare Sectors
Richard Snow (Trades, Portfolio) of Snow Capital Management released his first quarter holdings earlier today. These holdings highlight 121 stocks valued at $2.55 billion. The guru added 18 new stocks over the quarter for a quarter-over-quarter turnover of 17%. According to the fund’s Investing Philosophy, they look for companies that are financially strong, but with stock prices that have been depressed due to temporary or intermediate-term difficulties. Read more...
Groups of Gurus Trade Ten-Year Low P/B Stocks - CLH, IMO and TEVA
According to the GuruFocus Value Screen that shows value strategies of stocks traded at historical low P/B ratios, Teva Pharmaceutical Industries Ltd. (TEVA), Imperial Oil Ltd (IMO) and Clean Harbors Inc. (CLH) are held by numerous gurus and trading near their 10-year low. Here are the company updates and trading highlights as of the third quarter of 2013. Read more...
Bargain Hunting with Phenom Michael Price for 52-Week Lows
Guru Michael Price of MFP Investors LLC is a self-made investing phenom averaging a 12-month return of 84.84%. Over 12 months, Price is the fourth highest returning guru, following John Paulson at 296.45%, Michael Dell at 270.13% and Robert Karr at 89.84%. Read more...
Top Five Guru-Held Asian Companies as of the Second Quarter
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Asian countries were held by the highest number of gurus. The following five companies come from a variety of industries, are Asian-based and are held by the largest number of gurus. [b] Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.30
TEVA's P/E(ttm) is ranked higher than
90% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.30 vs. TEVA: 17.30 )
TEVA' s 10-Year P/E(ttm) Range
Min: 10.53   Max: 1042.5
Current: 17.3

10.53
1042.5
P/B 1.90
TEVA's P/B is ranked higher than
79% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. TEVA: 1.90 )
TEVA' s 10-Year P/B Range
Min: 1.37   Max: 7
Current: 1.9

1.37
7
P/S 2.18
TEVA's P/S is ranked higher than
77% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. TEVA: 2.18 )
TEVA' s 10-Year P/S Range
Min: 1.58   Max: 5.94
Current: 2.18

1.58
5.94
PFCF 29.02
TEVA's PFCF is ranked higher than
86% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TEVA: 29.02 )
TEVA' s 10-Year PFCF Range
Min: 9.63   Max: 64.03
Current: 29.02

9.63
64.03
EV-to-EBIT 16.92
TEVA's EV-to-EBIT is ranked higher than
86% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. TEVA: 16.92 )
TEVA' s 10-Year EV-to-EBIT Range
Min: 11.7   Max: 991
Current: 16.92

11.7
991
Shiller P/E 20.70
TEVA's Shiller P/E is ranked higher than
86% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 150.63 vs. TEVA: 20.70 )
TEVA' s 10-Year Shiller P/E Range
Min: 14.03   Max: 78.77
Current: 20.7

14.03
78.77
Current Ratio 1.14
TEVA's Current Ratio is ranked lower than
52% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. TEVA: 1.14 )
TEVA' s 10-Year Current Ratio Range
Min: 1.06   Max: 2.95
Current: 1.14

1.06
2.95
Quick Ratio 0.73
TEVA's Quick Ratio is ranked lower than
55% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. TEVA: 0.73 )
TEVA' s 10-Year Quick Ratio Range
Min: 0.68   Max: 2.19
Current: 0.73

0.68
2.19

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.22
TEVA's Dividend Yield is ranked higher than
76% of the 458 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. TEVA: 2.22 )
TEVA' s 10-Year Dividend Yield Range
Min: 0.18   Max: 2.76
Current: 2.22

0.18
2.76
Dividend Payout 0.38
TEVA's Dividend Payout is ranked higher than
78% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TEVA: 0.38 )
TEVA' s 10-Year Dividend Payout Range
Min: 0.04   Max: 5
Current: 0.38

0.04
5
Dividend growth (3y) 17.60
TEVA's Dividend growth (3y) is ranked higher than
89% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -0.10 vs. TEVA: 17.60 )
TEVA' s 10-Year Dividend growth (3y) Range
Min: -6.7   Max: 80.9
Current: 17.6

-6.7
80.9
Yield on cost (5-Year) 5.45
TEVA's Yield on cost (5-Year) is ranked higher than
95% of the 466 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. TEVA: 5.45 )
TEVA' s 10-Year Yield on cost (5-Year) Range
Min: 0.45   Max: 6.84
Current: 5.45

0.45
6.84
Share Buyback Rate 2.60
TEVA's Share Buyback Rate is ranked higher than
90% of the 561 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.50 vs. TEVA: 2.60 )
TEVA' s 10-Year Share Buyback Rate Range
Min: 2.6   Max: -10.9
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.87
TEVA's Price/DCF (Projected) is ranked higher than
96% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.06 vs. TEVA: 0.87 )
TEVA' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 29.17
Current: 0.87

0.6
29.17
Price/Median PS Value 0.64
TEVA's Price/Median PS Value is ranked higher than
95% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. TEVA: 0.64 )
TEVA' s 10-Year Price/Median PS Value Range
Min: 0.47   Max: 1.73
Current: 0.64

0.47
1.73
Price/Peter Lynch Fair Value 2.31
TEVA's Price/Peter Lynch Fair Value is ranked higher than
89% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TEVA: 2.31 )
TEVA' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.55   Max: 98.72
Current: 2.31

0.55
98.72
Earnings Yield (Greenblatt) 5.90
TEVA's Earnings Yield (Greenblatt) is ranked higher than
78% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. TEVA: 5.90 )
TEVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.6
Current: 5.9

0.1
8.6
Forward Rate of Return (Yacktman) 12.05
TEVA's Forward Rate of Return (Yacktman) is ranked higher than
83% of the 633 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.43 vs. TEVA: 12.05 )
TEVA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 6.6   Max: 37.5
Current: 12.05

6.6
37.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, AGN, FRX, MRX, ESALF » details
Traded in other countries:TEVJF.USA, TEV.Germany
Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Some of its products are Copaxone, Azilect & Provigil.
» More Articles for NYSE:TEVA

Headlines

Articles On GuruFocus.com
George Soros Reveals His Largest Stake Jul 23 2014 
George Soros Keeps Buying TEVA, EQT, YPF, EGN, CZR And Keeps Selling GOOGL, BA, MSFT, HAR Jul 16 2014 
Diamond Hill Capital Comments on Teva Pharmaceutical Industries Ltd Jun 26 2014 
Diamond Hill Select Fund Commentary – First Quarter 2014 Jun 25 2014 
Top Guru Held Asian Companies of the First Quarter Jun 03 2014 
George Soros Reports Top Five Stocks May 23 2014 
Richard Snow's Top Five Highlight Finance and Healthcare Sectors May 14 2014 
Wrong Marketing Lesson by Big Pharma May 03 2014 
Should You Buy Actavis? Mar 18 2014 
Forest Laboratories' Recovery Mar 18 2014 


More From Other Websites
Worth the Money? Assessing Executive Pay at Specialty Drug Makers Aug 27 2014
TEVA, VRX And AGN, Pushing Drugs Industry Downward Aug 25 2014
New Rules For Hydrocodone: What You Should Know Aug 22 2014
OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell... Aug 21 2014
Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company Aug 19 2014
Are Teva Pharmaceticals' Shares Poised for a Rebound? Aug 08 2014
Teva Comments on Receipt of First Paragraph IV Notice for COPAXONE® 40 mg/mL (glatiramer acetate... Aug 07 2014
Novo Nordisk, Mylan Miss Views; Mallinckrodt Beats Aug 07 2014
OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief... Aug 07 2014
OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief... Aug 07 2014
3 Stocks Pushing The Drugs Industry Downward Aug 06 2014
Did George Soros Sell His Stake In Israeli-Based SodaStream Because Of Political Reasons? Aug 04 2014
5 Drug Companies Profiting From Generics Aug 04 2014
Teva's Q2 Earnings & Revs Grow Y/Y, Updates Outlook Aug 01 2014
Why Teva Pharmaceutical (TEVA) Stock Is Lower Today Jul 31 2014
Teva Pharm raises full-year profit forecast after solid second quarter Jul 31 2014
Teva Pharm shareholder optimistic of change despite losing vote Jul 31 2014
[$$] Teva Pharmaceutical Swings to a Profit Jul 31 2014
Teva Pharm Q2 profit, revenue up on generic launches Jul 31 2014
Teva Quarterly Profit Rises on New Version of MS Drug Jul 31 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK